• darkblurbg

    Developing precision therapies

    for type 1 diabetes

  • darkblurbg

    Intralymphatic immunotherapy

    with Diamyd®

With all activities ongoing that further strengthen the foundation of Diamyd Medical, we are fortunate to have a strong financial position; more than SEK 200 million in cash as of today will carry us well into 2023.

Ulf Hannelius
President and CEO, Diamyd Medical AB
CEO Comments, Quarterly Report 1 21/22

Company Presentation

 December 20, 2021


 Dates for financial information and other events
January 26 − January 27, 2022
5th Antigen-Specific Immune Tolerance Summit
January 26, 2022
Quarterly Report I
Quarterly Report 1 2021/2022
March 30, 2022
Quarterly Report II
Quarterly Report 2 2021/2022
June 22, 2022
Quarterly Report III
Quarterly Report 3 2021/2022
October 5, 2022
Year-End Report
Year-End Report 2021/2022


Diamyd Medical develops therapies for type 1 diabetes
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)

Read More

Order GAD for preclinical research